Tokyo Tape
Sign in
← PHC Holdings

Quarterly report · Q3

6523.TEDINET S100SW3M
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥256.7bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥89.9bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥356.4bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥265.1bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥94.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income−¥5.1bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income−¥9.3bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥21.4bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥10.9bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax−¥13.8bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax−¥10.7bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥179m2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥7.4bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥4.0bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)−¥11.2bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥8.7bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥3.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥3.4bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income−¥11.2bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income−¥8.7bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥3.6bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥2.2bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥541.0bnat 2023-12-31Cons.Assets IFRS
Total assets¥561.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥569.9bnat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥416.7bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥422.7bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥124.3bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥138.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥138.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥136.1bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥124.7bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥138.0bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥137.9bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥43.9bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.9bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥59.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥28.5bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥21.4bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥6.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥17.1bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥17.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥11.3bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥31.1bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥40.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥32.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-88.72023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥-69.072023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥-25.842022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥27.332022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥17.692022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-88.72023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-69.072023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-25.842022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥27.072022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥17.532022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio23.0%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.6%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31¥1.8bn
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-12-31¥1.8bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥7.3bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue2023-04-01 → 2023-12-31¥80.3bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue external2023-04-01 → 2023-12-31¥80.3bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentsegment profit2023-04-01 → 2023-12-31¥8.8bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2023-04-01 → 2023-12-31¥79.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2023-04-01 → 2023-12-31¥79.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2023-04-01 → 2023-12-31¥4.9bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue2023-04-01 → 2023-12-31¥95.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue external2023-04-01 → 2023-12-31¥95.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentsegment profit2023-04-01 → 2023-12-31−¥11.6bn
—segment totalrevenue2023-04-01 → 2023-12-31¥254.9bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥254.9bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥2.1bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31¥1.8bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥1.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥13.0bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue2022-04-01 → 2022-12-31¥83.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue external2022-04-01 → 2022-12-31¥83.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentsegment profit2022-04-01 → 2022-12-31¥19.7bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2022-04-01 → 2022-12-31¥80.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2022-04-01 → 2022-12-31¥80.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.3bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue2022-04-01 → 2022-12-31¥99.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue external2022-04-01 → 2022-12-31¥99.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentsegment profit2022-04-01 → 2022-12-31¥8.5bn
—segment totalrevenue2022-04-01 → 2022-12-31¥263.3bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥263.3bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥34.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 875
ItemContextValueUnit
Changes in ownership interest in subsidiaries ss IFRSCurrentYTDDuration_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember－JPY
Changes in ownership interest in subsidiaries ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Changes in ownership interest in subsidiaries ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-1566000000JPY
Changes in ownership interest in subsidiaries ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-1044000000JPY
Changes in ownership interest in subsidiaries ss IFRSCurrentYTDDuration-2611000000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-66000000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration－JPY
Other ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Other ss IFRSCurrentYTDDuration_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember－JPY
Other ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Other ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember－JPY
Other ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember－JPY
Other ss IFRSCurrentYTDDuration－JPY
Total transactions with owners IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Total transactions with owners IFRSCurrentYTDDuration_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember－JPY
Total transactions with owners IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-66000000JPY
Total transactions with owners IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-10415000000JPY
Total transactions with owners IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-1232000000JPY
Total transactions with owners IFRSCurrentYTDDuration-11648000000JPY
Equity IFRSCurrentQuarterInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember38586000000JPY
Equity IFRSCurrentQuarterInstant_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember318000000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember38066000000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember124663000000JPY
Equity IFRSCurrentQuarterInstant_NonControllingInterestsIFRSMember-369000000JPY
Equity IFRSCurrentQuarterInstant124293000000JPY
Profit loss before tax IFRSPrior1YTDDuration7414000000JPY
Profit loss before tax IFRSCurrentYTDDuration-13778000000JPY
Depreciation expense ope cf IFRSPrior1YTDDuration22250000000JPY
Depreciation expense ope cf IFRSCurrentYTDDuration20458000000JPY
Impairment losses reversal of impairment losses ope cf IFRSPrior1YTDDuration375000000JPY
Impairment losses reversal of impairment losses ope cf IFRSCurrentYTDDuration16135000000JPY
Gain loss from financial assets measured at fair value through profit or loss ope cf IFRSPrior1YTDDuration6405000000JPY
Gain loss from financial assets measured at fair value through profit or loss ope cf IFRSCurrentYTDDuration-247000000JPY
Interest expenses ope cf IFRSPrior1YTDDuration4926000000JPY
Interest expenses ope cf IFRSCurrentYTDDuration5261000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration264000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration180000000JPY
Loss gain on sale of fixed assets ope cf IFRSPrior1YTDDuration-17000000JPY
Loss gain on sale of fixed assets ope cf IFRSCurrentYTDDuration-37000000JPY
Decrease increase in trade receivables ope cf IFRSPrior1YTDDuration-885000000JPY
Decrease increase in trade receivables ope cf IFRSCurrentYTDDuration11268000000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration-6068000000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-1573000000JPY
Increase decrease in trade payables ope cf IFRSPrior1YTDDuration-4581000000JPY
Increase decrease in trade payables ope cf IFRSCurrentYTDDuration-2955000000JPY
Increase decrease in retirement benefit liability ope cf IFRSPrior1YTDDuration56000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass